Skip to main content

Drug Interactions between Gemzar and Platinol

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

CISplatin gemcitabine

Applies to: Platinol (cisplatin) and Gemzar (gemcitabine)

In vitro and clinical studies have shown concurrent use of gemcitabine and cisplatin to have a synergistic effect. The precise mechanism of the interaction is unknown. The clearance of cisplatin is reduced during combination use. The clinical implications of these findings are unknown. Caution for increases in toxicity may be appropriate.

References

  1. Nakamura H, Yamaji Y, Fujita T, Fujita J, Takahara J "Synergistic growth inhibition of gemcitabine/cisplatin, and gemcitabine/etoposide on a human lung cancer cell line, RERF-LC-OK (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 36 (1995): a24251995
  2. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ "Interaction between cisplatin and gemcitabine in vitro and in vivo." Semin Oncol 22 (4 supp (1995): 72-9
  3. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer